fulvestrant has been researched along with Neutropenia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, F; Guindy, M; Kano, J; Ma, J | 1 |
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Callens, C; Canon, JL; Chakiba, C; Clatot, F; D'Hondt, V; Dalenc, F; de la Motte Rouge, T; Delaloge, S; Derbel, O; Dubot, C; Ferrero, JM; Frenel, JS; Garnier-Tixidre, C; Grenier, J; Hardy-Bessard, AC; Ladoire, S; Lemonnier, J; Levy, C; Lortholary, A; Mouret-Reynier, MA; Pierga, JY; Pistilli, B; Plaza, JE; Pradines, A; Sabatier, R; Stefani, L; Teixeira, L; Vegas, H | 1 |
| André, F; Appiah, AK; Chen, Y; Goel, S; Huynh, T; Tolaney, SM | 1 |
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L | 1 |
| Hara, F; Hashigaki, S; Huang, X; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Mukai, H; Muramatsu, Y; Nagasawa, T; Nakamura, R; Ohno, S; Rai, Y; Umeyama, Y | 1 |
2 review(s) available for fulvestrant and Neutropenia
| Article | Year |
|---|---|
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Neutropenia; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2023 |
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia | 2021 |
4 trial(s) available for fulvestrant and Neutropenia
| Article | Year |
|---|---|
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Lymphopenia; Mutation; Neutropenia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Piperazines; Placebos; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2019 |
1 other study(ies) available for fulvestrant and Neutropenia
| Article | Year |
|---|---|
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies | 2022 |